Can pharmacogenomics improve malaria drug policy?
نویسندگان
چکیده
منابع مشابه
Can pharmacogenomics improve malaria drug policy?
Coordinated global efforts to prevent and control malaria have been a tour-de-force for public health, but success appears to have reached a plateau in many parts of the world. While this is a multifaceted problem, policy strategies have largely ignored genetic variations in humans as a factor that influences both selection and dosing of antimalarial drugs. This includes attempts to decrease to...
متن کاملMalaria drug - resistance in Iran
Introduction: Malaria is a public health problem for approximately 2.4 billion people, 40% of the world’s population, particularly in the tropical and subtropical countries. Countries in Asia, and Latin America, the islands of the South, West, and central pacific ocean are all affected. Drug resistance is the greatest challenge in combating against malaria. Drug resistance in malaria is now w...
متن کاملUsing decision analysis to improve malaria control policy making.
Malaria and other vector-borne diseases represent a significant and growing burden in many tropical countries. Successfully addressing these threats will require policies that expand access to and use of existing control methods, such as insecticide-treated bed nets (ITNs) and artemesinin combination therapies (ACTs) for malaria, while weighing the costs and benefits of alternative approaches o...
متن کاملA Conceptual model on the pharmacogenomics implementation complications: An applied qualitative research based on national drug policy components
Introduction: Pharmacogenomics may well have substantial effects on the clinical, economic and regulatory aspects of health sector; which can lead to complications in access. Therefore, there is a need for evidence-based frameworks based on national drug policy components. The objective of the current study is to identify pharmacogenomics-based complications and develop a conceptual model. Mate...
متن کاملPharmacogenomics of GPCR Drug Targets
Natural genetic variation in the human genome is a cause of individual differences in responses to medications and is an underappreciated burden on public health. Although 108 G-protein-coupled receptors (GPCRs) are the targets of 475 (∼34%) Food and Drug Administration (FDA)-approved drugs and account for a global sales volume of over 180 billion US dollars annually, the prevalence of genetic ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Bulletin of the World Health Organization
سال: 2011
ISSN: 0042-9686
DOI: 10.2471/blt.11.087320